Is Coherus Oncology, Inc. CHRS stock halal to invest in?

No, as of August 2026, Coherus Oncology, Inc. stock (CHRS) is not currently classified as a Shariah compliant stock. This verdict follows the screening methodology of AAOIFI (the Accounting and Auditing Organization for Islamic Financial Institutions), whose Shariah Standard No. 21 is the leading global benchmark for screening halal stocks. To qualify as halal under this standard, a company must keep non-permissible income below 5% of total revenue, keep both interest-bearing investments and interest-bearing debt below 30% of market capitalisation, and have no impermissible preference share structure. Coherus Oncology, Inc. currently does not meet the threshold for the interest-bearing investments screen. Because screenings are refreshed monthly as new financial reports are published, a non-compliant stock can regain compliant status if its financial structure changes. You can track the latest status of Coherus Oncology, Inc. and discover Shariah compliant alternatives among the halal stocks in the Tabadulat app.

How often is Coherus Oncology, Inc. CHRS reviewed for Shariah compliance?

Tabadulat reviews Coherus Oncology, Inc. CHRS for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Coherus Oncology, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Non Permissible Income criteria?

Yes, as of August 2026, Coherus Oncology, Inc. stock (CHRS) passes the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. Coherus Oncology, Inc.'s income from non-permissible sources is currently within this 5% threshold. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Interest Bearing Investments criteria?

No, as of August 2026, Coherus Oncology, Inc. stock (CHRS) does not pass the AAOIFI interest-bearing investments screen. Under AAOIFI Shariah Standard No. 21, the cash a company places in interest-earning instruments (such as conventional deposits, bonds, treasury bills and money-market funds) must remain below 30% of its market capitalisation. Coherus Oncology, Inc.'s interest-bearing investments currently exceed this 30% limit, meaning too large a share of the company's value derives from riba-based instruments for the stock to qualify as halal on this criterion. The ratio moves with both the balance sheet and the share price, and is reassessed monthly.

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of August 2026, Coherus Oncology, Inc. stock (CHRS) passes the AAOIFI interest-bearing debt screen. Under AAOIFI Shariah Standard No. 21, a company's borrowings that accrue interest (conventional bank loans, bonds and similar riba-based financing) must remain below 30% of its market capitalisation. This cap limits shareholders' exposure to interest-based leverage. Coherus Oncology, Inc.'s interest-bearing debt is currently within the 30% threshold. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Coherus Oncology, Inc. CHRS stock?

Coherus Oncology, Inc. (CHRS) is currently classified as not Shariah compliant, so no dividend purification factor applies, because purification factors are calculated only for stocks that pass the AAOIFI screens. Purification (tazkiyah) is the practice of donating to charity the small portion of dividend income that stems from incidental non-permissible sources, such as interest earned on a compliant company's cash deposits. For non-compliant stocks the issue is not purification but eligibility: under AAOIFI Shariah Standard No. 21 the stock does not currently qualify as a halal investment. If Coherus Oncology, Inc. returns to compliance in a future monthly screening, its purification factor will be published alongside its updated status in the Tabadulat app.

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Preference Share screen?

Yes, as of August 2026, Coherus Oncology, Inc. stock (CHRS) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Coherus Oncology, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Coherus Oncology, Inc.

NASDAQ

Shariah-Compliant

Not Shariah

CHRS

About

Coherus Oncology, Inc.

CHRS

Coherus Biosciences Inc. is a biotechnology company focused on developing, manufacturing, and commercializing biosimilar products. Biosimilars are highly similar to existing, approved biological medicines with no clinically meaningful differences in terms of safety or efficacy. Coherus Biosciences aims to provide more accessible biological therapeutics in key therapeutic areas such as oncology, ophthalmology, and immunology. By doing so, the company addresses the need for more cost-effective treatment options and aims to contribute to the sustainability of healthcare systems globally. Coherus Biosciences operates within a highly regulated market, collaborating with healthcare providers, payers, and patients to enhance treatment options and availability. Founded in 2010 and headquartered in Redwood City, California, the company leverages its specialized research and development capabilities to expand its portfolio, providing competitive alternatives to high-cost biologics and playing a significant role in the biotechnology and healthcare sectors by fostering innovation and reducing healthcare costs.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

228

Website:

https://www.coherus.com

CHRS

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.

Coherus Oncology, Inc.

About

Coherus Oncology, Inc.

CHRS

Frequently asked questions

Is Coherus Oncology, Inc. CHRS stock halal to invest in?

How often is Coherus Oncology, Inc. CHRS reviewed for Shariah compliance?

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Non Permissible Income criteria?

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Interest Bearing Investments criteria?

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Interest Bearing Debt criteria?

What is the dividend purification factor for Coherus Oncology, Inc. CHRS stock?

Does Coherus Oncology, Inc. CHRS pass the AAOIFI Preference Share screen?

Can I buy Coherus Oncology (CHRS) stock on Tabadulat?

Open your account.

Deposit.

Screen.